Amar Bhat, MD
Cornea and External Diseases Specialist · Beaumont, TXNPI 1427443514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.
Across 105 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$559
- Alcon$258
- Mallinckrodt Hospital Products Inc.$207
- Heidelberg Engineering, Inc.$203
- Amgen$199
- Novartis$173
- plus $1K from 15 others
What the payments were for
- Food & beverage$2,50696%
- Education$984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $559 |
| Alcon | 11 | $258 |
| Mallinckrodt Hospital Products Inc. | 7 | $207 |
| Heidelberg Engineering, Inc. | 4 | $203 |
| Amgen(2 entities) | 10 | $199 |
| Novartis | 9 | $173 |
| Bausch & Lomb Americas Inc. | 5 | $140 |
| Ocular Therapeutix, Inc. | 11 | $138 |
| Oyster Point Pharma, Inc. | 6 | $118 |
| Rxsight Inc | 4 | $113 |
| Dompe US, Inc. | 3 | $73 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $66 |
| Glaukos Corporation | 2 | $63 |
| Kala Pharmaceuticals, Inc. | 3 | $62 |
| Carl Zeiss Meditec USA, Inc. | 1 | $50 |
| Biotissue Holdings Inc. | 2 | $49 |
| Tearlab Corp | 2 | $42 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $31 |
| Sanofi | 1 | $25 |
| Sight Sciences, Inc. | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectralis$135
- LUMIGAN$125
- ALPHAGAN P$125
How this compares
$2,604 in reported general payments places this provider in the 70th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $36,567 |
| LumiganBimatoprost | 49 | $29,069 |
| ProlensaBromfenac Sodium | 38 | $13,100 |
| VyzultaLatanoprostene Bunod | 27 | $11,338 |
| Prednisolone Acetate | 207 | $10,723 |
| TyrvayaVarenicline Tartrate | 14 | $9,422 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $7,298 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,983 |
| Latanoprost | 322 | $4,511 |
| Fluorometholone | 35 | $3,688 |
| MoxifloxacinMoxifloxacin Hcl | 156 | $3,419 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $2,897 |
| ErythromycinErythromycin Base | 213 | $2,110 |
| Brimonidine Tartrate | 38 | $2,055 |
| Timolol Maleate | 124 | $1,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $559 | $72,61994 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $66 | $13,10038 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $140 | $11,33827 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $118 | $9,42214 claims |
| AlconSimbrinza | $258 | $7,29822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in Beaumont
- Forrest SwannWaco$111K
- Stella KimHouston$58K
- Rachel GelmanMcAllen$54K
- Ravi PatelRound Rock$9K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Margaret HubbellTexarkana$4K
- Ardalan SharifiGalveston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.